Movement Alert|Alnylam Pharmaceuticals Falls 5.07% in Regular Trading, Trading at $229.555
Market Focus
Aug 21
On August 21, Alnylam Pharmaceuticals fell 5.07% in regular trading, trading at $229.555/share, with Turnover of $248 million.
Within the Biotechnology sector where Alnylam Pharmaceuticals belongs, the overall sector was broadly under pressure. Among individual stocks, Moderna down 22.46%, Amgen down 2.04%, Gilead Sciences down 1.87%, AbbVie down 0.82%, Hyperliquid Strategies Inc up 3.19%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.